Relying on scientific rigor and honesty, Origimm strives to establish itself as the leader in pioneering medical research that delivers superior products to prevent and treat skin microbiome-associated diseases.
We follow our vision by adhering to strong scientific and work ethics, mutual trust and concern for the good of others, including our patients, investors and business partners.
The skin microbiome is a large and diverse collection of bacteria, fungi, and viruses which inhabit the human skin. These microorganisms vary between individuals and between different skin sites.
The most of skin microbes are harmless or even beneficial to their host. However, among them are also present more virulent species which can take advantage of weakened immune defenses or changes in the skin protective barrier to induce skin diseases, wound infections or serious internal, life-threatening infections.
Origimm develops preventive and therapeutic products against the skin colonizing bacteria which can induce skin disease or infections at internal sites (e.g. infections associated with insertion of prosthetic implants or medical devices).
Our lead program is immune therapy against Propionibacterium acnes to treat acne vulgaris.
Additional programs include prophylactic immunization against Propionibacterium acnes and Staphylococcus epidermidis to prevent implant-associated infections.
Origimm (‘Origins of Immunity’) is an Austrian biotechnology company, which specializes in the discovery of antigens and functional drug targets for the prevention and treatment of infectious diseases and dermatological conditions associated with various microbial species. The company uses a proprietary technology to identify highly protective antigens and therapeutic targets by reverse functional screening, thereby significantly improving the success in the selection of the most effective preventive and therapeutic product candidates.
This page is dedicated to all of you who are not satisfied with currently available treatments
Origimm is developing safe and long-term effective therapies addressing the root cause of the disease, not only treating the symptoms.
This enables us to develop breakthrough therapies
Origimm (‘Origins of Immunity’) is a private Austrian biotechnology company, which specializes in the discovery of antigens and dermatological drug targets against diseases induced by the skin colonizing bacteria.
The company uses its proprietary technology to identify highly protective antigens and therapeutic targets by reverse functional screening, thereby significantly improving the success in the selection of the most effective preventive and therapeutic product candidates.